Marpai (MRAI) vs. Its Peers Head-To-Head Review

Marpai (NASDAQ:MRAIGet Rating) is one of 29 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it contrast to its competitors? We will compare Marpai to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Institutional & Insider Ownership

35.0% of Marpai shares are owned by institutional investors. Comparatively, 52.4% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by institutional investors. 41.4% of Marpai shares are owned by insiders. Comparatively, 22.2% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Marpai and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Marpai -100.92% -115.72% -61.22%
Marpai Competitors -1,770.64% -69.52% -27.58%

Analyst Recommendations

This is a summary of current ratings and target prices for Marpai and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marpai 0 0 1 0 3.00
Marpai Competitors 68 341 558 25 2.54

Marpai currently has a consensus price target of $2.50, indicating a potential upside of 151.71%. As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 51.55%. Given Marpai’s stronger consensus rating and higher possible upside, equities analysts plainly believe Marpai is more favorable than its competitors.

Valuation and Earnings

This table compares Marpai and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Marpai $14.23 million -$15.98 million -0.69
Marpai Competitors $2.07 billion $88.60 million 3.05

Marpai’s competitors have higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Marpai competitors beat Marpai on 7 of the 12 factors compared.

About Marpai

(Get Rating)

Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, health savings account administration, and cost containment services. It also develops artificial intelligence and healthcare technology that enables the analysis of data to predict and prevent events related to diagnostic errors, hospital visits, and administrative issues. The company was incorporated in 2021 and is headquartered in New York, New York.

Receive News & Ratings for Marpai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marpai and related companies with MarketBeat.com's FREE daily email newsletter.